[an error occurred while processing this directive]|[an error occurred while processing this directive]
乳腺癌术后内乳预防放疗的研究进展和临床决策
邓言波, 王淑莲
国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院放疗科 100021
Research progress and clinical decision of internal mammary prophylactic radiotherapy after breast cancer surgery
Deng Yanbo, Wang Shulian
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100021,China
Abstract：Although the internal mammary is the lymphatic drainage site for breast cancer,whether postoperative radiotherapy needs to be irradiated remains controversial. In recent years,several random studies have discussed internal mammary radiotherapy to varying degrees and no evidence has obtained that internal mammary radiotherapy bring clinical benefits to overall survival. In clinical practice,internal mammary prophylactic radiotherapy should maintain the balance among the risk of tumor recurrence,prescription dose and radiotherapy techniques to avoid the increased risk of radiotherapy-related death that offsets the possible survival benefits.
Deng Yanbo,Wang Shulian. Research progress and clinical decision of internal mammary prophylactic radiotherapy after breast cancer surgery[J]. Chinese Journal of Radiation Oncology, 2019, 28(12): 949-952.
[1]Huang O,Wang LP,Shen KW.et al. Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis:analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy[J]. Breast Cancer Res Treat,2008,107(3):379-387. DOI:10.1007/s10549-007-9561-4. [2]Chen L,Gu Y,Leaw S.et al. Internal mammary lymph node recurrence:rare but characteristic metastasis site in breast cancer[J]. BMC Cancer,2010.10:479. DOI:10.1186/1471-2407-10-479. [3]Veronesi U,Marubini E,Mariani L.et al. The dissection of internal mammary nodes does not improve the survival of breast cancer patients.30-year results of a randomised trial[J]. Eur J Cancer,1999,35(9):1320-1325. DOI:10.1016/s0959-8046(99)00133-1. [4]Overgaard M,Hansen PS,Overgaard J,et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial[J]. N Engl J Med,1997,337(14):949-955. DOI:10.1056/NEJM199710023371401. [5]Overgaard M,Jensen MB,Overgaard J.et al. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen:Danish Breast Cancer Cooperative Group DBCG 82c randomised trial[J]. Lancet,1999,353(9165):1641-1648. DOI:10.1016/S0140-6736(98)09201-0. [6]McGale P,Taylor C,Correa C,et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality:meta-analysis of individual patient data for 8135 women in 22 randomised trials[J]. Lancet,2014.383(9935):2127-2135. DOI:10.1016/S0140-6736(14)60488-8. [7]Hennequin,C. Bossard N,Servagi-Vernat S,et al. Ten-year survival results of a randomized trial of irradiation of internal mammary nodes after mastectomy[J]. Int J Radiat Oncol Biol Phys,2013.86(5):860-866. DOI:10.1016/j.ijrobp.2013.03.021. [8]Whelan TJ, Olivotto IA,Levine MN. Regional nodal irradiation in early-stage breast cancer[J]. N Engl J Med,2015,373(4):307-316. DOI:10.1056/NEJMc1510505. [9]Poortmans PM,Collette S,Kirkove C,et al. Internal mammary and medial supraclavicular irradiation in breast cancer[J]. N Engl J Med,2015,373(4):317-327. DOI:10.1056/NEJMoa1415369. [10]Thorsen LB,Offersen BV,Danø H,et al. DBCG-IMN:a population-based cohort study on the effect of internal mammary node irradiation in early node-positive breast cancer[J]. J Clin Oncol,2016,34(4):314-320. DOI:10.1200/JCO.2015.63.6456. [11]Fisher B,Jeong JH,Anderson S.et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy,total mastectomy,and total mastectomy followed by irradiation[J]. N Engl J Med,2002,347(8):567-575. DOI:10.1056/NEJMoa020128. [12]Giuliano AE,Ballman K,McCall L,et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases:long-term follow-up from the American college of surgeons oncology group (Alliance) ACOSOG Z0011 randomized trial[J]. Ann Surg,2016,264(3):413-420. DOI:10.1097/SLA.0000000000001863. [13]Punglia RS,Truong PT,Sadek BT,et al. Local therapy and survival in breast cancer[J]. N Engl J Med,2007,356(23):2399-2405. DOI:10.1245/s10434-014-3767-6. [14]Aleknavicius E,Atko$\hat{c}$iusKuzmickienel,et al. Postmastectomy internal mammary nodal irradiation:a long-term outcome[J]. Medicina (Kaunas),2014,50(4):230-236. DOI:10.1016/j.medici.2014.09.010. [15]Chang JS,Park W,Kim YB,et al. Long-term survival outcomes following internal mammary node irradiation in stage Ⅱ-Ⅲ breast cancer:results of a large retrospective study with 12-year follow-up[J]. Int J Radiat Oncol Biol Phys,2013,86(5):867-872. DOI:10.1016/j.ijrobp.2013.02.037. [16]Urano M,Denewar FA,Murai T,et al. Internal mammary lymph node metastases in breast cancer:what should radiologists know?[J]. Jpn J Radiol,2018,36(11):629-640. DOI:10.1007/s11604-018-0773-9. [17]Joo JH,Kim SS,Ahn SD,et al. Impact of pathologic diagnosis of internal mammary lymph node metastasis in clinical N2b and N3b breast cancer patients[J]. Breast Cancer Res Treat,2017,166(2):511-518. DOI:10.1007/s10549-017-4422-2. [18]Taylor CW,Wang Z,Macaulay E,et al. Exposure of the heart in breast cancer radiation therapy:a systematic review of heart doses published during 2003 to 2013[J]. Int J Radiat Oncol Biol Phys,2015,93(4):845-853. DOI:10.1016/j.ijrobp.2015.07.2292. [19]Darby SC,Ewertz M,McGale P,et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer[J]. N Engl J Med,2013,368(11):987-998. DOI:10.1056/NEJMoa1209825. [20]Taylor C,Correa C,Duane FK,et al. Estimating the risks of breast cancer radiotherapy:evidence from modern radiation doses to the lungs and heart and from previous randomized trials[J]. J Clin Oncol,2017,35(15):1641-1649. DOI:10.1200/JCO.2016.72.0722. [21]Jethwa KR,Kahila MM,Hunt KN,et al. Delineation of internal mammary nodal target volumes in breast cancer radiation therapy[J]. Int J Radiat Oncol Biol Phys,2017,97(4):762-769. DOI:10.1016/j.ijrobp.2016.11.037. [22]Xu Y,Wang J,Hu Z,et al. Locoregional irradiation including internal mammary nodal region for left-sided breast cancer after breast conserving surgery:Dosimetric evaluation of 4 techniques[J]. Med Dosim,2018. DOI:10.1016/j.meddos.2018.09.004. [23]Abo-Madyan Y,Aziz MH,Aly MM,et al. Second cancer risk after 3D-CRT,IMRT and VMAT for breast cancer[J]. Radiother Oncol,2014,110(3):DOI:10.1016/j.radonc.2013.12.002. [24]Grossman SA,Ellsworth S,Campian J,et al. Survival in patients with severe lymphopenia following treatment with radiation and chemotherapy for newly diagnosed solid tumors[J]. J Natl Compr Canc Netw,2015,13(10):1225-1231. DOI:10.6004/jnccn.2015.0151. [25]van den Bogaard VA,Ta BD,van der Schaaf A,et al. Validation and modification of a prediction model for acute cardiac events in patients with breast cancer treated with radiotherapy based on three-dimensional dose distributions to cardiac substructures[J]. J Clin Oncol,2017,35(11):1171-1178. DOI:10.1200/JCO.2016.69.8480. [26]Bazan J,DiCostanzo D,Kuhn K,et al. Likelihood of unacceptable normal tissue doses in breast cancer patients undergoing regional nodal irradiation in routine clinical practice[J]. Pract Radiat Oncol,2017,7(3):154-160. DOI:10.1016/j.prro.2016.10.012. [27]De Rose F,Cozzi L,Meattini I,et al. The potential role of intensity-modulated proton therapy in the regional nodal irradiation of breast cancer:a treatment planning study[J]. Clin Oncol (R Coll Radiol),2019,471-476. DOI:10.1016/j.clon.2019.07.016. [28]Thorsen LB,Thomsen MS,Berg M,et al. CT-planned internal mammary node radiotherapy in the DBCG-IMN study:benefit versus potentially harmful effects[J]. Acta Oncol,2014.53(8):1027-1034. DOI:10.3109/0284186X.2014.925579.
2019, Vol. 28 
